Successful Treatment of Paediatric Morphea with Tofacitinib

Authors

  • Jun-Chi Tang Department of Dermatology, Guangdong College of Clinical Dermatology, Anhui Medical University, Guangzhou, China
  • Wen-Yue Zheng 2Department of Dermatology and Rheumatology, Dermatology Hospital of Southern Medical University, Guangzhou, China
  • Guang-Ming Han 2Department of Dermatology and Rheumatology, Dermatology Hospital of Southern Medical University, Guangzhou, China
  • Shuang-fei Liu Department of Dermatology, Guangdong College of Clinical Dermatology, Anhui Medical University, Guangzhou, China
  • Bin Yang Department of Dermatology, Guangdong College of Clinical Dermatology, Anhui Medical University, Guangzhou, China

DOI:

https://doi.org/10.2340/actadv.v103.4805

Keywords:

Scleroderma, Localized, tofacitinib, Biopsy, Myofibroblasts

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Albuquerque JVD, Andriolo BN, Vasconcellos MR, Civile VT, Lyddiatt A, Trevisani VF. Interventions for morphea. Cochrane Database Syst Rev 2019; 7: CD005027.

https://doi.org/10.1002/14651858.CD005027.pub5 DOI: https://doi.org/10.1002/14651858.CD005027.pub5

You H, Xu D, Zhao J, Li J, Wang Q, Tian X, et al. JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol 2020; 59: 334-351.

https://doi.org/10.1007/s12016-020-08786-6 DOI: https://doi.org/10.1007/s12016-020-08786-6

Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, et al. JAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with morphea. J Invest Dermatol 2020; 140: 1446-1449.

https://doi.org/10.1016/j.jid.2019.12.019 DOI: https://doi.org/10.1016/j.jid.2019.12.019

Richard SA. Exploring the pivotal immunomodulatory and anti-inflammatory potentials of glycyrrhizic and glycyrrhetinic acids. Mediators Inflamm 2021; 2021: 6699560.

https://doi.org/10.1155/2021/6699560 DOI: https://doi.org/10.1155/2021/6699560

Kelsey CE, Torok KS. The localized scleroderma cutaneous assessment tool: responsiveness to change in a pediatric clinical population. J Am Acad Dermatol 2013; 69: 214-220.

https://doi.org/10.1016/j.jaad.2013.02.007 DOI: https://doi.org/10.1016/j.jaad.2013.02.007

Groot N, de Graeff N, Avcin T, Bader-Meunier B, Brogan P, Dolezalova P, et al. European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 2017; 76: 1788-1796.

https://doi.org/10.1136/annrheumdis-2016-210960 DOI: https://doi.org/10.1136/annrheumdis-2016-210960

Stevens WG, Gould DJ, Pham LD, Jimenez Lozano JN. Molecular and histological evidence detailing clinically observed skin improvement following cryolipolysis. Aesthet Surg J 2022; 42: 56-67.

https://doi.org/10.1093/asj/sjab226 DOI: https://doi.org/10.1093/asj/sjab226

Wang P, Guo W, Liu S. A rare case of juvenile localised scleroderma with intra-oral and dental involvement. Exp Ther Med 2015; 10: 2213-2215.

https://doi.org/10.3892/etm.2015.2791 DOI: https://doi.org/10.3892/etm.2015.2791

Kumar AB, Blixt EK, Drage LA, El-Azhary RA, Wetter DA. Treatment of morphea with hydroxychloroquine: a retrospective review of 84 patients at Mayo clinic, 1996-2013. J Am Acad Dermatol 2019; 80: 1658-1663.

https://doi.org/10.1016/j.jaad.2019.01.040 DOI: https://doi.org/10.1016/j.jaad.2019.01.040

Walker D, Susa JS, Currimbhoy S, Jacobe H. Histopathological changes in morphea and their clinical correlates: results from the morphea in adults and children cohort V. J Am Acad Dermatol 2017; 76: 1124-1130.

https://doi.org/10.1016/j.jaad.2016.12.020 DOI: https://doi.org/10.1016/j.jaad.2016.12.020

Torok KS, Kurzinski K, Kelsey C, Yabes J, Magee K, Vallejo AN, et al. Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheu 2015; 45: 284-293.

https://doi.org/10.1016/j.semarthrit.2015.06.006 DOI: https://doi.org/10.1016/j.semarthrit.2015.06.006

Chakraborty D, Šumová B, Mallano T, Chen C, Distler A, Bergmann C, et al. Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat Commun 2017; 8: 1130.

https://doi.org/10.1038/s41467-017-01236-6 DOI: https://doi.org/10.1038/s41467-017-01236-6

Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, et al. PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production. Sci Transl Med 2018; 10: eaar8356.

https://doi.org/10.1126/scitranslmed.aar8356 DOI: https://doi.org/10.1126/scitranslmed.aar8356

Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal 2017; 15: 23.

https://doi.org/10.1186/s12964-017-0177-y DOI: https://doi.org/10.1186/s12964-017-0177-y

McGaugh S, Kallis P, De Benedetto A, Thomas RM. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a literature review. Dermatol Ther 2022; 35: e15437.

https://doi.org/10.1111/dth.15437 DOI: https://doi.org/10.1111/dth.15437

Published

2023-04-21

How to Cite

Tang, J.-C., Zheng, W.-Y., Han, G.-M., Liu, S.- fei, & Yang, B. (2023). Successful Treatment of Paediatric Morphea with Tofacitinib. Acta Dermato-Venereologica, 103, adv4805. https://doi.org/10.2340/actadv.v103.4805